I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ASH 2022

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Jul 6 / Roche and Genentech
Mosunetuzumab with Polatuzumab Vedotin is Effective and has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
Subgroup analysis of a Phase Ib/II study of intravenous mosunetuzumab plus polatuzumab vedotin (NCT03671018) in patients aged <65 and ≥65 years with relapsed/refractory diffuse large B-cell lymphoma.

Sign up or login to unlock the full suite of MEDICALLY features

Jul 6 / Roche and Genentech
SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin versus Rituximab in Combination with Gemcitabine plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Rationale and study design of the Phase III SUNMO trial in progress (NCT05171647), comparing subcutaneous mosunetuzumab plus intravenous polatuzumab vedotinin versus rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Sign up or login to unlock the full suite of MEDICALLY features

Jul 6 / Roche and Genentech
Subcutaneous Mosunetuzumab isActive with a Manageable Safety Profilein Patients with Relapsed/Refractory(R/R) B-cell Non-Hodgkin Lymphomas(B-NHL): Updated Results from a PhaseI/II Study
Updated results from a Phase I/II dose-escalation and expansion study (NCT02500407) of subcutaneous mosunetuzumab treatment in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.